Literature DB >> 794063

Biosynthesis of norvaline, norleucine, and homoisoleucine in Serratia marcescens.

M Kisumi, M Sugiura, I Chibata.   

Abstract

The biosynthetic pathways of norvaline homoisoleucine were examined using regulatory mutants of leucine biosynthesis in Serratia marcescens. alpha-Isopropylmalate synthetase [EC 4.1.3.12], the first enzyme of leucine biosynthesis, catalyzed the condensations of acetyl-CoA with pyruvate, alpha-ketobutyrate, alpha-ketovalerate, or alpha-keto-beta-methylvalerate as well as alpha-ketoisovalerate. These condensations were inhibited by leucine in the alpha-aminobutyrate-resistant mutant, a mutant with derepressed leucine biosynthetic enzymes. However, these condensations were coordinately desensitized in the isoleucine leaky revertant, a leucine accumulator. The formation of norvaline or homoisoleucine was greater in the leucine accumulator, but its leucine auxotroph did not form these unnatural amino acids. Thus, norvaline and homoisoleucine are considered to be formed from alpha-ketobutyrate and alpha-keto-beta-methylvalerate by the leucine biosynthetic enzymes. This view was confirmed by the findings that a norvaline accumulator could be obtained by derivation of the leucine accumulator into an isoleucine-valine auxotroph. Norleucine was also found to be formed from alpha-ketovalerate, an alpha-ketoacid corresponding to norvaline.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 794063     DOI: 10.1093/oxfordjournals.jbchem.a131281

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  21 in total

Review 1.  Editing of errors in selection of amino acids for protein synthesis.

Authors:  H Jakubowski; E Goldman
Journal:  Microbiol Rev       Date:  1992-09

2.  Degenerate connective polypeptide 1 (CP1) domain from human mitochondrial leucyl-tRNA synthetase.

Authors:  Qing Ye; Meng Wang; Zhi-Peng Fang; Zhi-Rong Ruan; Quan-Quan Ji; Xiao-Long Zhou; En-Duo Wang
Journal:  J Biol Chem       Date:  2015-08-13       Impact factor: 5.157

3.  Amino acid toxicities of Escherichia coli that are prevented by leucyl-tRNA synthetase amino acid editing.

Authors:  Vrajesh A Karkhanis; Anjali P Mascarenhas; Susan A Martinis
Journal:  J Bacteriol       Date:  2007-09-21       Impact factor: 3.490

4.  Investigation into the misincorporation of norleucine into a recombinant protein vaccine candidate.

Authors:  Joyce Ni; Meg Gao; Andrew James; Jiansheng Yao; Tao Yuan; Bruce Carpick; Tony D'Amore; Patrick Farrell
Journal:  J Ind Microbiol Biotechnol       Date:  2015-04-05       Impact factor: 3.346

Review 5.  Norvaline and norleucine may have been more abundant protein components during early stages of cell evolution.

Authors:  Claudia Alvarez-Carreño; Arturo Becerra; Antonio Lazcano
Journal:  Orig Life Evol Biosph       Date:  2013-09-08       Impact factor: 1.950

6.  Depression of by-product formation during L: -isoleucine production by a living-cell reaction process.

Authors:  Masato Terasawa; Masayuki Inui; Makoto Goto; Yasurou Kurusu; Hideaki Yukawa
Journal:  Appl Microbiol Biotechnol       Date:  1991-06       Impact factor: 4.813

7.  From amino acid to glucosinolate biosynthesis: protein sequence changes in the evolution of methylthioalkylmalate synthase in Arabidopsis.

Authors:  Jan-Willem de Kraker; Jonathan Gershenzon
Journal:  Plant Cell       Date:  2011-01-04       Impact factor: 11.277

8.  Top-Down Mass Spectrometry Analysis of Membrane-Bound Light-Harvesting Complex 2 from Rhodobacter sphaeroides.

Authors:  Yue Lu; Hao Zhang; Weidong Cui; Rafael Saer; Haijun Liu; Michael L Gross; Robert E Blankenship
Journal:  Biochemistry       Date:  2015-12-02       Impact factor: 3.162

9.  l-Isoleucine Production with Corynebacterium glutamicum: Further Flux Increase and Limitation of Export.

Authors:  S Morbach; H Sahm; L Eggeling
Journal:  Appl Environ Microbiol       Date:  1996-12       Impact factor: 4.792

Review 10.  Metabolic engineering for advanced biofuels production from Escherichia coli.

Authors:  Shota Atsumi; James C Liao
Journal:  Curr Opin Biotechnol       Date:  2008-09-12       Impact factor: 9.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.